Key result
Diabetic retinopathy and skin advanced glycation end-products predict major CV events in type 2 diabetes.
Why the study?
Risk of cardiovascular events is not homogeneous in subjects with type 2 diabetes, and early identification of high-risk patients remains a challenge.
Do diabetic retinopathy and skin tissue advanced glycation end products predict cardiovascular events in patients with type 2 diabetes?
Cohort (n=260)
Do diabetic retinopathy and skin tissue advanced glycation end products predict cardiovascular events in patients with type 2 diabetes?
Answers are grounded in this paper and cite their sources.
Diabetic retinopathy and skin tissue advanced glycation end-products serve as independent predictors of cardiovascular events in patients with type 2 diabetes, potentially aiding in risk stratification.
Risk of cardiovascular events is not homogeneous in subjects with type 2 diabetes; therefore, its early identification remains a challenge to be met. The aim of this study is to evaluate whether the presence of diabetic retinopathy and accumulation of advanced glycation end-products in subcutaneous tissue can help identify patients at high risk of cardiovascular events. For this purpose, we conducted a prospective study (mean follow-up: 4.35 years) comprising 200 subjects with type 2 diabetes with no history of clinical cardiovascular disease and 60 non-diabetic controls matched by age and sex. The primary outcome was defined as the composite of myocardial infarction, coronary revascularization, stroke, lower limb amputation or cardiovascular death. The Cox proportional hazard multiple regression analysis was used to determine the independent predictors of cardiovascular events. The patients with type 2 diabetes had significantly more cardiovascular events than the non-diabetic subjects. Apart from the classic factors such as age, sex and coronary artery calcium score, we observed that the diabetic retinopathy and advanced glycation end-products in subcutaneous tissue were independent predictors of cardiovascular events. We conclude that the diabetic retinopathy and advanced glycation end-products in subcutaneous tissue could be useful biomarkers for selecting type 2 diabetic patients in whom the screening for cardiovascular disease should be prioritized, thereby creating more personalized and cost-effective medicine.
No takes yet. Share an insight, caveat, or question.
Planas et al. (2021) conducted a cohort in Type 2 diabetes (n=260). Diabetic retinopathy and skin tissue advanced glycation end-products vs. Absence of these biomarkers / non-diabetic controls was evaluated on Composite of myocardial infarction, coronary revascularization, stroke, lower limb amputation or cardiovascular death. Diabetic retinopathy and skin tissue advanced glycation end-products were independent predictors of cardiovascular events in patients with type 2 diabetes over a mean 4.35-year follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: